Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorsRudolph L. Leibel, Marija Dokmanovic-Chouinard, Wendy K. Chung, Charles LeDuc, Stuart G. Fischer
Estimating the term…
The invention provides methods for reducing diabetes susceptibility in a subject and methods for increasing the expression of LL or CLORF32 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ll RNA or Clorf32 RNA comprising contacting a cell with an agent; determining expression of the Ll RNA or Clorf32 RNA in the presence and the absence of the agent; and comparing expression of the Ll RNA or Clorf32 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ll RNA or Clorf32 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.
A method for identifying an agent which modulates expression of a murine Ll RNA , the method comprising:
A method for identifying an agent which modulates expression of a human C1orf32 RNA , the method comprising:
A method for identifying an agent which modulates expression of an mRNA encoding a murine LL protein, or a fragment or an isoform thereof, the method comprising:
A method for identifying an agent which modulates expression level of an mRNA encoding the protein encoded by human C1ORF32 gene, the method comprising:
A method for identifying an agent which modulates expression of murine Ll RNA , the method comprising:
A method for identifying an agent which modulates expression of C1orf32 RNA, the method comprising:
A method for identifying an agent which modulates expression of an LL murine protein, the method comprising:
A method for identifying an agent which modulates expression of human C1ORF32 protein, the method comprising:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:72 or an isolated peptide which is at least 75% identical to SEQ ID NO:
An isolated peptide consisting essentially of the amino acid sequence of SEQ ID NO:
An isolated nucleic acid consisting essentially of SEQ ID NO:
An isolated nucleic acid consisting essentially of SEQ ID NO:
A method for detecting a predisposition to type 2 diabetes in a subject, the method comprising determining expression of C1orf32 RNA or C1ORF32 protein in a sample obtained from a subject, wherein decreased expression, compared to expression in a control sample from a subject known not to have type 2 diabetes, indicates that the subject is susceptible to type II diabetes.
A method for manipulating beta cell mass to treat a biological condition in a subject, comprising contacting a beta cell precursor with an agent which increases expression of C1orf32 mRNA or C1ORF32 protein, thereby manipulating beta cell mass in the subject.
A method for treating a biological condition associated with reduced beta cell mass in a subject, comprising administering to the subject an agent which increases expression of C1orf32 mRNA or C1ORF32, so as to increase beta cell mass in the subject thereby treating the biological condition.
A method for treating a biological condition associated with reduced levels of C1orf32 mRNA or C1ORF32 in a subject, comprising administering an agent which increases expression of C1orf32 mRNA or C1ORF32, thereby treating the biological condition.
A method for increasing expression of C1orf32 RNA or C1ORF32 protein in a pancreatic cell, the method comprising contacting the cell with an agent which increases the levels of the C1orf32 RNA or C1ORF32 protein.
A method of modulating beta cell development, the method comprising contacting a pancreatic cell with an agent which increases the levels of C1orf32 mRNA or C1ORF32 protein.
A method for increasing beta cell mass, beta cell numbers or beta cell proliferation, the method comprising contacting a pancreatic cell with an agent which increases expression of C1orf32 mRNA or C1ORF32 protein.
A method for treating a pre-diabetic or a diabetic subject, the method comprising administering to the subject a therapeutically effective amount of an agent which increases the expression of C1orf32 mRNA or C1ORF32 protein.
A method for treating a subject suffering from a disease or disorder associated with defects in beta cell mass, beta cell proliferation or beta cell activity, the method comprising:
A method for manipulating beta cell mass to treat a biological condition in a subject, comprising contacting a beta cell precursor with a peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or a C1ORF32 functional fragment, or any combination thereof, thereby manipulating beta cell mass in the subject.
A method for treating a biological condition associated with reduced beta cell mass in a subject, comprising administering to the subject a peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or a C1ORF32 functional fragment, or any combination thereof, so as to increase beta cell mass in the subject thereby treating the biological condition.
A method for treating a pre-diabetic or a diabetic subject, the method comprising administering to the subject a therapeutically effective amount of a peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or a C1ORF32 functional fragment, or any combination thereof.
A peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or a C1ORF32 functional fragment for use in treating a pre-diabetic or a diabetic condition in a subject.
A peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or a C1ORF32 functional fragment for use in treating a biological condition associated with reduced beta cell mass in a subject.
A peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or a C1ORF32 functional fragment for use in manipulating beta cell mass to treat a biological condition in a subject.
An antibody that specifically binds to a peptide having SEQ ID NO:1-9 or 69-72, or a C1ORF32 protein, a C1ORF32 polypeptide, a C1ORF32 isoform, or any fragment thereof.
Dependencies are inferred from the claim text.